Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
IQ-AI ( (GB:IQAI) ) just unveiled an announcement.
IQ-AI Limited’s subsidiary, Imaging Biometrics, has applied for the FDA’s Breakthrough Therapy Designation for its oral gallium maltolate (GaM) therapy, aimed at treating recurrent or refractory glioblastoma (GBM) IDH-wildtype. Preliminary results from the Phase 1 trial show a promising overall survival rate of 34.1 months, significantly higher than the standard treatment’s median of 14-15 months. This designation, if granted, would provide more intensive FDA guidance and support, potentially impacting the company’s market position and offering hope for improved GBM treatments.
More about IQ-AI
Imaging Biometrics, LLC is a wholly-owned subsidiary of IQ-AI Limited, focusing on delivering quantitative imaging platforms and therapeutics to enhance clinical diagnosis and treatment efficiency and effectiveness.
YTD Price Performance: -38.21%
Average Trading Volume: 626,352
Technical Sentiment Signal: Strong Buy
Current Market Cap: £2.13M
Find detailed analytics on IQAI stock on TipRanks’ Stock Analysis page.